US equities
|
NVDA
$236.43
▲+2.41%
MU
$1,083.05
▼-1.31%
TSLA
$371.92
▲+5.03%
SPCX
$157.09
▲+6.09%
SNDK
$1,740.71
▼-2.63%
AMD
$634.33
▲+3.02%
STX
$825.51
▼-12.70%
WDC
$406.07
▼-12.21%
NVDA
$236.43
▲+2.41%
MU
$1,083.05
▼-1.31%
TSLA
$371.92
▲+5.03%
SPCX
$157.09
▲+6.09%
SNDK
$1,740.71
▼-2.63%
AMD
$634.33
▲+3.02%
STX
$825.51
▼-12.70%
WDC
$406.07
▼-12.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Candel Therapeutics, Inc. - Common Stock
(NQ:
CADL
)
10.19
+0.03 (+0.30%)
Delayed Quote
Updated: 12:18 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Candel Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
Today 9:00 EDT
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate
October 01, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
September 30, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
September 30, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
September 10, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present at September Investor Conferences
August 26, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 13, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
↗
August 12, 2026
Candel Therapeutics (NASDAQ:CADL) is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief...
Via
MarketBeat
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
August 03, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
July 29, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
June 30, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
June 25, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
June 02, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data
↗
May 20, 2026
Candel Therapeutics (NASDAQ:CADL) Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer...
Via
MarketBeat
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
May 15, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 14, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present at Upcoming Investor Conferences
May 13, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
May 04, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
April 29, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
March 17, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 12, 2026
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
March 09, 2026
From
Candel Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
